Targeting FGFR: Urothelial Cancer and Beyond (Podcast Pearls)

Experts, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss the most recent clinical data on targeting FGFR in urothelial cancer and beyond.
Alison Birtle, MD, FRCP, FRCR
person default
Ignacio Duran, MD, PhD
Format: Adobe Acrobat (.pdf)
File Size: 122 KB
Released: April 1, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Janssen Pharmaceutica NV

Related Content

Slides from Arjun Balar, MD on optimal selection of first-line treatment for patients with advanced urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: May 6, 2021

Expert insight from Arjun Balar, MD, on choosing optimal first-line therapy for patients with advanced urothelial or bladder cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 6, 2021 Expired: May 5, 2022

Expert insight from Arjun Balar, MD, on choosing optimal therapy for patients with advanced urothelial cancer after chemo and IO, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 4, 2021 Expired: May 3, 2022

Slides from Arjun Balar, MD on the role of antibody-drug conjugates in early stage urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: May 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue